JP2022535093A5 - - Google Patents

Info

Publication number
JP2022535093A5
JP2022535093A5 JP2021571882A JP2021571882A JP2022535093A5 JP 2022535093 A5 JP2022535093 A5 JP 2022535093A5 JP 2021571882 A JP2021571882 A JP 2021571882A JP 2021571882 A JP2021571882 A JP 2021571882A JP 2022535093 A5 JP2022535093 A5 JP 2022535093A5
Authority
JP
Japan
Prior art keywords
deuterium
dimethyltryptamine
enriched mixture
pharmaceutically acceptable
mixture according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571882A
Other languages
English (en)
Japanese (ja)
Other versions
JP7523474B2 (ja
JP2022535093A (ja
Filing date
Publication date
Priority claimed from GBGB1907871.6A external-priority patent/GB201907871D0/en
Application filed filed Critical
Publication of JP2022535093A publication Critical patent/JP2022535093A/ja
Publication of JP2022535093A5 publication Critical patent/JP2022535093A5/ja
Application granted granted Critical
Publication of JP7523474B2 publication Critical patent/JP7523474B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571882A 2019-06-03 2020-06-02 重水素化された又は部分的に重水素化されたn,n-ジメチルトリプタミン化合物を含む治療用組成物 Active JP7523474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1907871.6 2019-06-03
GBGB1907871.6A GB201907871D0 (en) 2019-06-03 2019-06-03 Therapeutic compositions
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Publications (3)

Publication Number Publication Date
JP2022535093A JP2022535093A (ja) 2022-08-04
JP2022535093A5 true JP2022535093A5 (cg-RX-API-DMAC10.html) 2023-05-30
JP7523474B2 JP7523474B2 (ja) 2024-07-26

Family

ID=67385960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571882A Active JP7523474B2 (ja) 2019-06-03 2020-06-02 重水素化された又は部分的に重水素化されたn,n-ジメチルトリプタミン化合物を含む治療用組成物

Country Status (20)

Country Link
US (3) US12076311B2 (cg-RX-API-DMAC10.html)
EP (2) EP4062910B1 (cg-RX-API-DMAC10.html)
JP (1) JP7523474B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240142567A (cg-RX-API-DMAC10.html)
CN (1) CN114096246B (cg-RX-API-DMAC10.html)
AU (1) AU2020286709B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021024333A2 (cg-RX-API-DMAC10.html)
CA (2) CA3142290C (cg-RX-API-DMAC10.html)
DK (1) DK3826632T3 (cg-RX-API-DMAC10.html)
EA (1) EA202193338A1 (cg-RX-API-DMAC10.html)
ES (1) ES2922101T3 (cg-RX-API-DMAC10.html)
GB (4) GB201907871D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20220837T8 (cg-RX-API-DMAC10.html)
HU (1) HUE059439T2 (cg-RX-API-DMAC10.html)
IL (1) IL288617B2 (cg-RX-API-DMAC10.html)
MX (1) MX2021014728A (cg-RX-API-DMAC10.html)
PL (1) PL3826632T3 (cg-RX-API-DMAC10.html)
PT (1) PT3826632T (cg-RX-API-DMAC10.html)
TW (1) TWI860478B (cg-RX-API-DMAC10.html)
WO (1) WO2020245133A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) * 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
GB2605144A (en) * 2021-03-22 2022-09-28 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
CN116056763B (zh) * 2020-06-02 2024-03-05 赛本英国有限公司 包含氘代或部分氘代的n,n-二甲基色胺化合物的治疗组合物
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4138818B1 (en) * 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3216889A1 (en) * 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
EP4792879A2 (en) * 2021-05-17 2026-08-19 Cybin IRL Limited Formulations of psilocybin
KR20240013170A (ko) * 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023028091A1 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Deuterated empathogens
CA3229910A1 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
AU2022342266B2 (en) * 2021-09-08 2026-03-26 Cybin Irl Limited Combination drug therapies
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
WO2023076135A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250205198A1 (en) * 2022-03-31 2025-06-26 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
TW202617141A (zh) 2024-07-10 2026-05-01 英商賽本英國有限公司 包含氘化n,n-二甲基色胺之醫藥組合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
AU1928892A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
WO2001097779A2 (en) 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
WO2008049116A2 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
US20100069399A1 (en) * 2008-09-15 2010-03-18 Auspex Pharmaceutical, Inc. Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
JP7273731B2 (ja) 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
CN109251151A (zh) * 2017-07-12 2019-01-22 北京广为医药科技有限公司 N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
DK3927338T3 (da) 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CA3188263A1 (en) 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
EP4138818B1 (en) 2020-08-28 2024-08-21 Cybin UK Ltd Injectable formulation
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
EP4221682A2 (en) 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations

Similar Documents

Publication Publication Date Title
JP2023527575A5 (cg-RX-API-DMAC10.html)
JP2021505575A5 (cg-RX-API-DMAC10.html)
JP2018168191A5 (cg-RX-API-DMAC10.html)
JP2022502500A5 (cg-RX-API-DMAC10.html)
IL298542B1 (en) Therapeutic solid dosage forms comprising deuterated n,n-dimethyltryptamine compounds and salts thereof
JP2022514089A5 (cg-RX-API-DMAC10.html)
JP2016510317A5 (cg-RX-API-DMAC10.html)
JP2023103256A (ja) 非ラセミ混合物およびその使用
JP2015526458A5 (cg-RX-API-DMAC10.html)
JP2005538099A5 (cg-RX-API-DMAC10.html)
RU2005104418A (ru) Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин
JPWO1993011765A1 (ja) (+)アポビンカミン酸2−ニトロキシエチルエステルの新規な用途
JP2023550149A5 (cg-RX-API-DMAC10.html)
RU2012153164A (ru) Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути
IL273169B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
JP7801365B2 (ja) 環状ケトン系化合物の新たな使用
CN104010636A (zh) 三环化合物、包含它们的组合物及其用途
JP2019529460A5 (cg-RX-API-DMAC10.html)
CN103889409A (zh) N-羟基-4-{2-[3-(n,n-二甲基氨基甲基)苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的给药方案
JP2024531799A5 (cg-RX-API-DMAC10.html)
JP2023552862A5 (cg-RX-API-DMAC10.html)
JP2024500632A5 (cg-RX-API-DMAC10.html)
JP2020502106A5 (cg-RX-API-DMAC10.html)
WO2021186325A1 (en) Almitrine for treating the hypoxemia of a coronavirus infection
JP2022550040A5 (cg-RX-API-DMAC10.html)